ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

イマチニブメシル酸塩

Imatinib Mesylate

HCID 123596
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
220127-57-1
標準SMILES
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
InChIKey
YLMAHDNUQAMNNX-UHFFFAOYSA-N
分子式
C30H35N7O4S
平均分子量
589.7 g/mol
単同位体質量
589.2471238

概要

Imatinib methanesulfonate is a methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an anticoronaviral agent, an antineoplastic agent, a tyrosine kinase inhibitor and an apoptosis inducer. It contains an imatinib.

名称と識別子

優先名称
Imatinib Mesylate
IUPAC
methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
現地名
イマチニブメシル酸塩
英語名
Imatinib mesylate
分子式
C30H35N7O4S
分子量
589.71

名称と別名

Imatinib mesylate220127-57-1GleevecGlivecImatinib mesilateimatinib methanesulfonatesti-571Imatinib accordImatinib medacImatinib (as mesilate)STI 571IMKELDI
名称をさらに表示
メシル酸イマチニブグリベックイマチニブメシル酸塩イマチニブメタンスルホン酸塩グリーベック (メシル酸イマチニブ)メシル酸イマチニブ (CGP-5714CGP-57148B1)イマチニブメシル酸塩 (JAN)イマチニブ・メシル酸グレエベックイマチニブ・メタンスルホン酸ノマチニブメシル酸塩N-[3-[[4-(3-ピリジニル)ピリミジン-2-イル]アミノ]-4-メチルフェニル]-4-(4-メチルピペラジン-1-イルメチル)ベンズアミド・メタンスルホン酸塩N-[3-[[4-(3-ピリジニル)ピリミジン-2-イル]アミノ]-4-メチルフェニル]-4-[(4-メチルピペラジン-1-イル)メチル]ベンズアミド・メタンスルホン酸イマチニブメシラート4-[(4-メチルピペラジン-1-イル)メチル]-N-[4-メチル-3-[[4-(3-ピリジル)ピリミジン-2-イル]アミノ]フェニル]ベンズアミド・メタンスルホン酸グリーベックCGP 57148matinib MesylateImatinib (Glivec)4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonateGleevacCGP54148BGenfatinib
imatinib oralNSC-716051DTXSID9040502QTI-571Imatinib methane sulfonateQTI5718A1O1M485BDTXCID7020502

物性

構造計算による物性補完中

極性表面積
149 Ų
水素結合供与体数
3
水素結合受容体数
10
回転可能結合数
7
重原子数
42
形式電荷
0
複雑度
799

実験および物理化学的性質

Color/FormWhite to off white to brownish or yellowish tinged crystalline powder
Solubility · 2 件

Soluble in aqueous buffers =<pH 5.5, but very slightly soluble in neutral to alkaline aqueous buffers; freely soluble to very soluble in dimethyl sulfoxide, methanol, and ethanol; insoluble in n-octanol, acetone, and acetonitrile.

In water, >100 g/l @ pH 4.2; 49 mg/l @ pH 7.4

Human Drugs · 5 件

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting PointMP: 226 °C (alpha form); 217 °C (beta form)
Other Experimental Properties · 2 件

Lipophilic at pH 7.4

Molecular weight: 493.60; melting point: 211-213 °C; pKa1: 8.07; pKa2: 3.73; pKa3: 2.56; pKa 4: 1.52 /Imatinib/

物理化学的性質

融点
214 · 214-224°C
貯蔵温度
2 · 2-8°C
溶解性

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 0.9% (1 of 117) of reports.

Danger

H302 (82.9%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 117 reports by companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

FDA Requirements · 2 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl imatinib mesylate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Special Reports · 2 件

The purpose of this report is to summarize ... /a drug/ recently approved by the U.S. Food and Drug Administration. ... Gleevec (imatinib mesylate) ... for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors ... . Gleevec /was/ an accelerated approval and supplemental new drug application (NDA); ... .[Cohen MH et al; US FDA Drug Approval Summaries: Imetinib Mesylate, Mesna Tablets, and Zoledronic Acid; Oncologist 7 (5): 393-400 (2002).]

Imatinib is ... a new drug being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and patients with Philadelphia chromosome-positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alfa.[Baker DE; Imatinib mesylate; Rev Gastroenterol Disord 2 (2): 75-86 (2002).]

化学と産業

薬理情報

Mechanism of Action · 2 件

Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. In colony formation assays using ex vivo peripheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positive colonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as well as Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.

Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF=and SCF-mediated cellular events, In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

Biological Half-LifeElimination - Approximately 18 and 40 hours, for imatinib and its primary metabolite, respectively.
Metabolism/Metabolites · 1 件

CYP3A4 is the major enzyme responsible for metabolism of imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to imatinib. The plasma AUC for this metabolite is about 15% of the AUC for imatinib.

FDA Pharmacological Classification · 4 件

IMATINIB MESYLATE

Protein Kinase Inhibitors [MoA]; Cytochrome P450 2D6 Inhibitors [MoA]; Bcr-Abl Tyrosine Kinase Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Kinase Inhibitor [EPC]

IMATINIB ORAL

Kinase Inhibitor [EPC]; Cytochrome P450 3A4 Inhibitors [MoA]; Cytochrome P450 2D6 Inhibitors [MoA]; Bcr-Abl Tyrosine Kinase Inhibitors [MoA]

MeSH Pharmacological Classification

関連反応

41 件
反応記録を作成
HRID 15376 の反応式
HRID 15376生成物として
HRID 59044 の反応式
HRID 59044生成物として
HRID 225501 の反応式
HRID 225501反応物として
HRID 550780 の反応式
HRID 550780生成物として
HRID 553430 の反応式
HRID 553430生成物として
HRID 562558 の反応式
HRID 562558生成物として
HRID 562559 の反応式
HRID 562559生成物として
HRID 562560 の反応式
HRID 562560生成物として
前へ1 / 6 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
220127-57-1
PubChem CID
123596
DTXSID
DTXSID9040502
ChEMBL
CHEMBL1642
ChEBI
CHEBI:31690
UNII
8A1O1M485B
EC Number
606-892-3、933-289-5
2 O: · H2O: 可溶10mg/mL、透明
外見
白い固体
色
白からベージュ
水溶解度
100 mg/mL · water: 100mg/mL
安定性
-20 °C · -20°C の DMSO または水溶液で最大 3 か月間保存できます。
InChIKey
YLMAHDNUQAMNNX-UHFFFAOYSA-N
SMILES
C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)(=O)C1=CC=C(CN2CCN(C)CC2)C=C1.CS(O)(=O)=O
CAS データベース
220127 · 220127-57-1(CAS DataBase Reference)

化学的性質

化学的特性Off-White Solid

Hazard Classes and CategoriesAcute Tox. 4 (82.9%)

安全と保護具

Disposal Methods · 1 件

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

毒性情報

Interactions · 5 件

In this study /an investigation was conducted to study/ the effect of concomitant administration of imatinib and idarubicin, an anthracycline with haematosuppressive activity, in nu/nu mice and murine bone marrow cells. Double-treated animals showed significantly increased mortality compared to mice that received imatinib or idarubicin alone only when idarubicin and imatinib were given simultaneously. The combined treatment induced a more severe neutropenia with a slower recovery when compared to mice treated with idarubicin alone. The myeloid metaplasia usually observed in the spleen after idarubicin treatment was absent in mice co-treated with imatinib. Bone marrow from double-treated animals also showed decreased numbers of megakaryocytes and myeloid precursor cells. In vitro culture of murine bone marrow cells in the presence of imatinib inhibited SCF-induced proliferation and recovery from treatment with idarubicin. ... Results indicate that the simultaneous administration of imatinib enhances idarubicin-induced hematopoietic toxicity in vivo and in vitro.

Caution is recommended when administering Gleevec /imatinib/ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin). Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concetrations.

Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations. Co-medications that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, or St. John's Wort) may reduce exposure to Gleevec /imatinib/. ...A patient on chronic therapy with phenytoin... given 350 mg daily dose of Gleevec had an AUC0-24 about one-fifth of the typical AUC0-24 of 20 ug/hr/mL. This probably reflects the induction of CYP3A4 by phenytoin.

Imatinib increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by imatinib. Particular caution is recommended when administering Gleevec /imatinib/ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide). Gleevec will increase plasma concentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).

For more Interactions (Complete) data for IMATINIB MESYLATE (6 total), please visit the HSDB record page.

Milk Concentrations · 1 件

In lactating female rats administered 100 mg/kg ... imatinib and/or its metabolites were extensively excreted in milk. It is estimated that approximately 1.% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Imatinib mesylate

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5 件

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ An oral dose of 1200 mg/sq m/day .... was not lethal to rats following 14 days of administration. A dose of 3600 mg/sq m/day ... was lethal to rats after 7-10 administrations, due to general deterioration of the animals with secondary degenerative histological changes in many tissues.

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Severe liver toxicity was observed in dogs treated for 2 weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia. Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralization and dilation of the renal tubules and tubular nephrosis. Increased BUN and creatinine were observed in several of these animals. An increased rate of opportunistic infections was observed with chronic imatinib treatment. In a 39-week monkey study, treatment with imatinib resulted in worsening of normally suppressed malarial infections in these animals. Lymphopenia was observed in animals (as in humans).

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In a study of fertility, in male rats dosed for 70 days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60 mg/kg ...This was not seen at doses </=20 mg/kg ... When female rats were dosed 14 days prior to mating and through to gestational day 6, there was no effect on mating or on number of pregnant females. At a dose of 60 mg/kg ..., female rats had significant post-implantation fetal loss and a reduced number of live fetuses. This was not seen at doses </=20 mg/kg ...

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Imatinib mesylate was teratogenic in rats when administered during organogenesis at doses >/=100 mg/kg ... Teratogenic effects included exencephaly or encephalocele, absent/reduced frontal and absent parietal bones. Female rats administered this dose also experienced significant post-implantation loss in the form of early fetal resorption. At doses higher than 100 mg/kg, total fetal loss was noted in all animals. These effects were not seen at doses </=30 mg/kg ...

/GENOTOXICITY/ Positive genotoxic effects were obtained for imatinib in an in vitro mammalian cell assay (Chinese hamster ovary) for clastogenicity (chromosome aberrations) in the presence of metabolic activation. Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay. one of these intermediates was also positive in the mouse lymphoma assay. Imatinib was not genotoxic when tested in an in vitro bacterial cell assay (Ames test), an in vitro mammalian cell assay (mouse lymphoma) and in vivo rat micronucleus assay.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

法規制情報

FDA Requirements · 2 件

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl imatinib mesylate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
3
rtecs
CV5520550
hs_code
29350090
risk_code
22
hazard_code
Xn
Hazard Classifications
Repr. 2
ストレージクラス
11 - Combustible Solids
有毒物質データの
220127-57-1(Hazardous Substances Data)
· 2 件

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

Absorption, Distribution and Excretion · 4 件

Imatinib is well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose. Mean absolute bioavailability for the capsule formulation is 98%. Following oral administration in healthy volunteers, the elimination half-lives of imitanib and its major active metabolite, the N-desmethyl derivative, were approximately 18 and 40 hours, respectively. Mean imatinib AUC increased proportionally with increasing dose in the range 25 mg-1000 mg. There was no signficant change in the pharmacokinetics of imatinib on repeated dosing, and accumulation is 1.5-2.5 fold at steady state when Gleevec is dosed once daily. At clinically relevant concentrations of imatinib, binding to plasma proteins in in vitro experiments is approximately 95%, mostly to albumin and (alpha)1-acid glycoprotein.

Fecal /elimination/ - 68% within 7 days (20% of dose unchanged); Renal /elimination/ - 13% within 7 days (5% of dose unchanged).

Typically, clearance of imitanib in a 50-year-old patient weighing 50 kg is expected to be 8 L/hr, while for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/hr. However, the inter-patient variability of 40% in clearance does not warrant initial dose adjustment based on body weight and/or age but indicates the need for close monitoring for treatment related toxicity.

In lactating female rats administered 100 mg/kg ... imatinib and/or its metabolites were extensively excreted in milk. It is estimated that approximately 1.% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight.

用途と製造

UsesMEDICATION
General Manufacturing Information... distributed by Novartis Pharmaceuticals Corp., East Hanover, NJ 07936
応用分野 · 5 件

解説グリベックは,慢性骨髄性白血病などに対する分子標的治療薬「イマチニブ」の商品名。小学館 デジタル大辞泉について 情報 | 凡例

用途Bcl-Abl チロシンキナーゼを ATP 競合的に阻害作用を示します。

説明In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. This compound can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloride of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.

使用Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib

一般的な説明Imatinib is available in 100- and 400-mg capsules for oraladministration and is indicated for the treatment of CML,gastrointestinal stromal tumors (GIST) that express Kit andacute lymphoplastic leukemia that is positive for thePhiladelphia chromosome.Bioavailability of the agent is nearly 100% by the oralroute. The agent is highly protein bound and metabolized tothe N-desmethyl derivative by CYP3A4-mediated removalof the piperazinyl methyl group. The resulting metabolite issimilar to the parent in activity. Elimination occurs primarilyin the feces, and the terminal half-life is 18 hours forthe parent and 40 hours of the N-desmethyl metabolite.Resistant forms of the TK are known, which have alteredamino acids that prevent binding. In addition, there may beincreased levels of the kinase itself. The drug is also a substratefor Pgp and an additional efflux transporter known asbreast cancer resistance protein (BCRP), both of which removethe drug from the cell. These transporters are also inhibitedby the agent as well. Severe side effects include ascites,neutropenia, thrombocytopenia, skin rash, andpulmonary edema. Less serious side effects include nausea/vomiting, heartburn, and headache but overall, the agentis better tolerated than most other medications used in treatingthe disease.

補足説明

定義ChEBI: A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.